Literature DB >> 8045724

Recoverin is highly uveitogenic in Lewis rats.

I Gery1, N P Chanaud, E Anglade.   

Abstract

PURPOSE: Recoverin, a calcium-binding protein that selectively localizes to the retina and pineal gland, has been identified as the target for the putative pathogenic autoimmune process of cancer-associated retinopathy (CAR). The present study was aimed at testing the capacity of recoverin to induce experimental autoimmune uveoretinitis and pinealitis in Lewis rats.
METHODS: Lewis rats were immunized against recombinant myristoylated recoverin by a single footpad injection of the protein, at various doses, emulsified in complete Freund's adjuvant. Development of uveoretinitis was monitored by clinical and histologic examinations, whereas pinealitis was detected by histologic examination.
RESULTS: Immunization with recoverin induced severe panuveitic changes that closely resemble those induced by S-antigen (arrestin). The effect was dose-dependent, with 10 micrograms/rat the lowest immunopathogenic dose. Rats immunized with recoverin also developed pineal inflammation.
CONCLUSION: Recoverin is highly immunopathogenic in Lewis rats. Although the ocular changes induced in rats differ from those seen in CAR, the data recorded here are in line with the concept that recoverin can initiate pathogenic autoimmune processes in the eye.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8045724

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  13 in total

Review 1.  Sympathetic ophthalmia: an autoimmune ocular inflammatory disease.

Authors:  C C Chan; M Mochizuki
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Past and Present Behçet's Disease Animal Models.

Authors:  Jermilia Charles; Francis J Castellino; Victoria A Ploplis
Journal:  Curr Drug Targets       Date:  2020       Impact factor: 3.465

3.  S antigen specific effector T cell activation detected by cytokine flow cytometry.

Authors:  J P Morgan; R A Robins; H S Dua; P J Tighe
Journal:  Br J Ophthalmol       Date:  2002-05       Impact factor: 4.638

4.  Recoverin, a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy.

Authors:  A S Polans; D Witkowska; T L Haley; D Amundson; L Baizer; G Adamus
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

5.  High incidence of antibodies to lens proteins in sera from patients with uveitis.

Authors:  Deshka Doycheva; Doycheva Deshka; Beate Preuss; Preuss Beate; Reinhild Klein; Klein Reinhild; Manfred Zierhut; Zierhut Manfred
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-09-19       Impact factor: 3.535

6.  Expression of a photoreceptor protein, recoverin, as a cancer-associated retinopathy autoantigen in human lung cancer cell lines.

Authors:  S Matsubara; Y Yamaji; M Sato; J Fujita; J Takahara
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

Review 7.  Experimental autoimmune uveitis and other animal models of uveitis: An update.

Authors:  Svati Bansal; Veluchamy A Barathi; Daiju Iwata; Rupesh Agrawal
Journal:  Indian J Ophthalmol       Date:  2015-03       Impact factor: 1.848

8.  A case of paraneoplastic optic neuropathy and outer retinitis positive for autoantibodies against collapsin response mediator protein-5, recoverin, and α-enolase.

Authors:  Michiyuki Saito; Wataru Saito; Atsuhiro Kanda; Hiroshi Ohguro; Susumu Ishida
Journal:  BMC Ophthalmol       Date:  2014-01-16       Impact factor: 2.209

9.  Sympathetic ophthalmia: to the twenty-first century and beyond.

Authors:  Xi K Chu; Chi-Chao Chan
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-06-01

10.  Proteomic surveillance of retinal autoantigens in endogenous uveitis: implication of esterase D and brain-type creatine kinase as novel autoantigens.

Authors:  Yoko Okunuki; Yoshihiko Usui; Takeshi Kezuka; Takaaki Hattori; Kayo Masuko; Hiroshi Nakamura; Kazuo Yudoh; Hiroshi Goto; Masahiko Usui; Kusuki Nishioka; Tomohiro Kato; Masaru Takeuchi
Journal:  Mol Vis       Date:  2008-06-12       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.